| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
$37.8 million net revenue for Q3 2026, driven by $34.0 million in revenue from MIPLYFFA |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Comp... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 |
| 16 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
BOSTON, Mass., Mar. 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreeme... |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
The Employment Agreement (“Agreement” is made and entered into effective as of March 9, 2026 by and between Zevra Therapeutics, Inc., a Delaware corporation (the “Company”), including its affiliates, parent, subsidiaries, successors, and... |
| 17 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
(c) On December 11, 2025, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Timothy Sangiovanni, the Company’s current Senior Vice President, Finance and Corporate Controller and principal account... |
| 02 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Celebration, FL – December 2, 2025– Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the appointment of Alic... |
| 20 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Celebration, FL – November 20, 2025– Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced today that its Chief Financia... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA® net revenue of $22.4 million |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million |
| 29 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 29, 2025, Zevra Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”) for the following purposes: |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million |
| 07 Apr 2025 |
8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
Celebration, FL – Apr. 7, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced the closing of the sale of... |
| 11 Mar 2025 |
8-K: Results of Operations and Financial Condition
FY 2024 net revenue of $23.6 million, driven by record product net revenue of $10.2 million during |
| 27 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
Celebration, FL – Feb. 27, 2025 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into ... |
| 06 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Celebration, Fla – Dec. 6, 2024 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes ... |
| 22 Nov 2024 |
8-K: Regulation FD Disclosure; Other Events
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C |
| 12 Nov 2024 |
8-K: Results of Operations and Financial Condition
FDA approval of MIPLYFFATM and product launch cap third quarter filled with multiple commercial |
| 20 Sep 2024 |
8-K: Regulation FD Disclosure; Other Events
MIPLYFFA is the first FDA-approved treatment for Niemann-Pick disease type C (NPC), an ultra-rare and progressive neurodegenerative disease |
Loading...